Methods for the prophylactic and therapeutic treatment of cardiac tissue damage
AssigneeEast Tennessee State University
InventorsDavid L. Williams, Chuanfu Li
Life of this patent
Estimating the term…
Abstract
The invention provides a method for treating tissue damage caused by ischemia/reperfusion, microbial infection, or sepsis using (1→3)-β-D-glucans to modulate immune response mediators and their effects.
Claims26
A method for reducing cardiac tissue ischemia/reperfusion damage in a mammalian subject having an acute ischemic condition or proximately under a condition associated with an imminent onset of ischemia, comprising administering to the subject a therapeutic dosage of about 1 mg to about 150 mg of a (1-3)-β-D-glucan per kilogram of the subject's body weight, wherein said (1-3)-β-D-glucan is selected from the group consisting of glucan sulphate, glucan phosphate, scleroglucan, or a combination thereof.
A method for treating ischemia/reperfusion injury in a body organ of a mammalian subject having an acute ischemic condition or proximately under a condition associated with an imminent onset of ischemia in the organ, comprising administering to the subject a therapeutic dosage of about 1 mg to 150 mg of a (1-3)-β-D-glucan per kilogram of the subject's body weight, wherein said (1-3)-β-D-glucan is selected from the group consisting of glucan sulphate, glucan phosphate, scleroglucan, or a combination thereof.
A therapeutic method for decreasing ischemia/reperfusion damage in a mammalian subject having an acute ischemic condition caused by a spinal cord injury or proximately under a trauma from a spinal cord injury comprising administering to a subject a therapeutically effective dosage of (1→3)-β-D-glucan, wherein said (1-3)-β-D-glucan is selected from the group consisting of glucan sulphate, glucan phosphate, scleroglucan, or a combination thereof.
A therapeutic method for reducing ischemic injury to living tissue in a body limb of a mammalian subject proximately under an acute trauma associated with the onset of ischemia comprising systemically administering to a subject a therapeutically effective dosage of (1→3)-β-D-glucan, wherein said (1-3)-β-D-glucan is selected from the group consisting of glucan sulphate, glucan phosphate, scleroglucan, or a combination thereof.
Dependencies are inferred from the claim text.